Joseph Kim, MD
Associate Professor of Internal Medicine (Medical Oncology)Cards
Appointments
Additional Titles
Director, Prostate Cancer Research
Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Contact Info
Appointments
Additional Titles
Director, Prostate Cancer Research
Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Contact Info
Appointments
Additional Titles
Director, Prostate Cancer Research
Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Contact Info
About
Titles
Associate Professor of Internal Medicine (Medical Oncology)
Director, Prostate Cancer Research; Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Biography
Dr. Joseph Kim is a board-certified medical oncologist and a Director of the Prostate Cancer Research Program for Prostate and Urological Cancers DART of Yale Cancer Center. He is a recipient of the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI) and a recipient of other awards from Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Dr. Kim has led several peer-reviewed, NCI-sponsored, investigator-initiated clinical trials in prostate cancer, bladder cancer, and other solid tumors as a study chair.
Dr. Joseph Kim serves as an author/editor of the genitourinary (GU) cancers chapter of ASCO-SEP, an educational textbook for medical oncologists, and a co-editor of the GU cancers section of a peer-reviewed journal, Current Oncology Report, and ad hoc reviewer of multiple oncology journals. He has been invited as a speaker for numerous international and national academic conferences including GU Cancers Symposium, ASCO Annual Meeting, CTEP/ NCI meeting, ASCO Direct highlights, International Genitourinary Cancer Conference, and many others.
His passion lies in delivering compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder, and other urinary tract cancer, testicular cancer, and penile cancer. He is also passionate about developing and executing hypothesis-driven clinical trials of novel therapies in GU cancers and other solid tumors.
Appointments
Medical Oncology
Associate Professor on TermPrimary
Other Departments & Organizations
- Cancer Signaling Networks
- Early Drug Development Program
- Early Phase Clinical Trial Program
- Internal Medicine
- Medical Oncology
- Prostate & Urologic Cancers Program
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
Education & Training
- Fellow
- National Institutes of Health (2013)
- Resident
- Emory University School of Medicine (2010)
- MD
- Wake Forest University School of Medicine (2007)
- BA
- Covenant College, Biology, Pre-Medicine (2001)
Research
Overview
Clinical Trials - Early Phase; Cancer therapies; Androgen Receptor, DNA Repair Pathways; mTOR pathways; Cancer immunotherapy
ORCID
0000-0003-2222-3531
Research at a Glance
Yale Co-Authors
Publications Timeline
Daniel P. Petrylak, MD
Insoo Kang, MD
Patricia LoRusso, DO
Joseph Vinetz, MD, FACP, FIDSA, FASTMH, BS
Junghee Jenny Shin, MD, PhD
Peter M. Glazer, MD, PhD
Publications
2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy S, Eder J, Deng Y, LoRusso P, Kim J, Patel A. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO Precision Oncology 2024, 8: e2300289. PMID: 38412387, PMCID: PMC10914240, DOI: 10.1200/po.23.00289.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCell-free circulating tumor DNANon-small-cell lung cancerSmall-cell lung cancerTriple-negative breast cancerPancreatic ductal adenocarcinomaAdvanced solid tumorsVariant allele fractionRadiographic responseOverall survivalCombination therapySolid tumorsCtDNA levelsLung cancerPretreated advanced solid tumorsDays of combination therapyMetastatic pancreatic ductal adenocarcinomaResponse to anticancer therapyAssociated with disease progressionProgression-free survivalPlasma samplesLead-inPoly(ADP-riboseInferior OSTumor DNASurvival outcomes
2022
Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProstate cancer patientsCOVID-19 outcomesCancer patientsPoor COVID-19 outcomesAndrogen-androgen receptorExpression of TMPRSS2COVID-19 infectionSARS-CoV-2Directed therapyMean hospitalizationPCa patientsHospitalization ratesPCa casesRetrospective analysisOutcome differencesPatientsDefinitive conclusionsStatistical significanceData generate hypothesesHospitalizationTherapyTMPRSS2Cellular entryOutcomesARDTRandomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal Of Clinical Oncology 2022, 41: 871-880. PMID: 36256912, PMCID: PMC9901975, DOI: 10.1200/jco.21.02947.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic castration-resistant prostate cancerRadiographic progression-free survivalMedian radiographic progression-free survivalCastration-resistant prostate cancerArm AProstate cancerAdverse eventsGrade 3Progressive metastatic castration-resistant prostate cancerEndothelial growth factor receptor inhibitorEnd pointHomologous recombination repair genesGrowth factor receptor inhibitorsPrimary end pointSecondary end pointsProgression-free survivalRecombination repair genesPoly (ADP-ribose) polymerase inhibitionTreat setTreat patientsClinical outcomesRandomized trialsPreclinical modelsReceptor inhibitorsCediranibEmerging Role of PARP Inhibitors in Metastatic Prostate Cancer
Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022, 24: 1619-1631. PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPARP inhibitorsBRCA2 mutationsProstate cancerFDA approvalMetastatic prostate cancer patientsAccelerated FDA approvalDeleterious BRCA2 mutationsHRR gene mutationsObjective response ratePhase II studyMetastatic prostate cancerProstate cancer patientsPoly (ADP-ribose) polymerase (PARP) inhibitorsUS FDA approvalSomatic mutationsMCRPC patientsCombination regimenII studyClinical benefitRadium-223Cancer patientsStandard treatmentAndrogen receptorDNA damage repair pathwaysClinical developmentEffect of androgen receptor directed therapy in prostate cancer patients with COVID-19.
Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.Peer-Reviewed Original ResearchConceptsProstate cancerPCa patientsAndrogen receptorCOVID-19Mortality rateYale New Haven Health SystemProtective rolePrevalence of PCaRate of hospitalRetrospective chart reviewExpression of TMPRSS2Rate of hospitalizationProstate cancer patientsAndrogen receptor antagonistProstate cancer casesSARS-CoV-2Institutional review boardDirected therapyChart reviewClinical characteristicsGnRH agonistHormone therapyGnRH antagonistHome medicationsClinical outcomes
2021
Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives
Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives. Kompass Nutrition & Dietetics 2021, 1: 72-90. DOI: 10.1159/000519151.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSupportive careDigital health solutionsHealth solutionsHealth economic endpointsOncology supportive careRoutine supportive careHealthcare resource utilizationOptimal supportive careImprovement of QoLTreatment of symptomsPatient-centered careEvidence-based therapeutic interventionsDifferent healthcare systemsUnplanned hospitalizationMost patientsSymptom supportOncology practiceSymptom distressClinical studiesPatient managementOral drugsSymptom monitoringPatient complianceTreatment efficacyTherapeutic interventionsClinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic pancreatic adenocarcinomaHomologous recombination DNA repair deficiencyMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaOlaparib combinationStable diseaseBRCA mutationsAdverse eventsDuctal adenocarcinomaCommon treatment-related adverse eventsVascular endothelial growth factor receptor inhibitorEndothelial growth factor receptor inhibitorTreatment-related adverse eventsGrowth factor receptor inhibitorsPrior systemic chemotherapyMedian overall survivalObjective response rateGermline BRCA mutationsBest overall responseExpression of BRCA1/2Restaging scanCancer cell linesPrimary endpointStudy drugSystemic chemotherapySapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2- mutated metastatic urothelial carcinoma (mUC).
Kim J, Milowsky M, Hahn N, Kwiatkowski D, Morgans A, Davis N, Appleman L, Gupta S, Lara P, Hoffman-Censits J, Quinn D, Shyr Y, LoRusso P, Sklar J, Petrylak D. Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2- mutated metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2021, 39: 431-431. DOI: 10.1200/jco.2021.39.6_suppl.431.Peer-Reviewed Original ResearchCitationsConceptsMetastatic urothelial carcinomaStable diseaseAdverse eventsObjective responseWithdrew consentTSC2 mutationsUrothelial carcinomaTSC1 mutationsTumor samplesCommon adverse eventsMedian overall survivalTreatment-related deathsPhase II studyCentral labOverall response rateDual mTORC1/2 inhibitorUnknown mutational statusCentral confirmationEligible patientsEvaluable patientsMUC patientsRestaging scanII studyPrimary endpointBaseline characteristicsSafety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyAtezolizumab in Castration-Resistant Prostate Cancer
Petrylak DP, Loriot Y, Shaffer DR, Braiteh F, Powderly J, Harshman LC, Conkling P, Delord JP, Gordon M, Kim JW, Sarkar I, Yuen K, Kadel EE, Mariathasan S, O'Hear C, Narayanan S, Fassò M, Carroll S, Powles T. Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyAtezolizumab in Castration-Resistant Prostate Cancer. Clinical Cancer Research 2021, 27: 3360-3369. PMID: 33568344, DOI: 10.1158/1078-0432.ccr-20-1981.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerPartial responseProstate cancerAtezolizumab monotherapyOverall survivalPrior linesImmune-related response criteriaTreatment-related adverse eventsDose-expansion studyPSA response rateMedian overall survivalBiomarker analysisEvaluable patientsRECIST 1.1Adverse eventsOS ratesClinical benefitSafety profileDisease progressionAtezolizumabClinical activityRadiographic assessmentImmune responseLimited efficacy
2020
Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer
Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee M, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer. BJU International 2020, 127: 435-444. PMID: 32969563, PMCID: PMC8265825, DOI: 10.1111/bju.15227.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic castration-resistant prostate cancerDocetaxel/prednisoneCastration-resistant prostate cancerPhase 1 studyProstate cancerDose of cabozantinibEfficacy of cabozantinibPalmar-plantar erythrodysesthesiaPhase 1/2 trialPhase 2 studyOverall survival timeDocetaxel/Median TTPNeutropenic feverPoor accrualThromboembolic eventsMore patientsRandomized studyMedian timeMulticentre studyGrade 3Survival timeCabozantinibPrednisonePatients
Clinical Trials
Current Trials
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
HIC ID2000033530RoleSub InvestigatorPrimary Completion Date07/18/2025Recruiting ParticipantsA Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
HIC ID2000027706RoleSub InvestigatorPrimary Completion Date06/29/2026Recruiting ParticipantsA Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
HIC ID2000032119RoleSub InvestigatorPrimary Completion Date03/17/2026Recruiting ParticipantsA Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
HIC ID2000032170RoleSub InvestigatorPrimary Completion Date12/01/2027Recruiting ParticipantsOpen Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors
HIC ID2000032542RolePrincipal InvestigatorPrimary Completion Date01/01/2026Recruiting Participants
Academic Achievements & Community Involvement
activity ASCO-SEP
Journal ServiceEditorDetails11/01/2021 - Presentactivity Current Oncology Reports
Journal ServiceEditorDetails02/01/2015 - Presentactivity Frontiers Oncology
Journal ServiceReviewerDetails07/01/2019 - Presentactivity American Society of Clinical Oncology
Professional OrganizationsMemberDetails07/05/2010 - Presentactivity Society of Immunotherapy of Cancer
Professional OrganizationsMemberDetails07/01/2013 - Present
Clinical Care
Overview
Joseph Kim, MD, is an associate professor at Yale School of Medicine and the director of Prostate Cancer Research at Yale Cancer Center. A Yale Medicine oncology specialist, he delivers compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder cancer, testicular cancer, and penile cancer. Dr. Kim offers advanced treatments, such as cancer immunotherapy and oral inhibitors based on genomic biomarkers for prostate cancer and bladder cancer.
His research interests encompass developing novel anti-cancer therapies for genitourinary cancers through early phase clinical trials. Dr. Kim's research also explores changes in tumor DNA during treatment for patients with advanced prostate cancer.
Dr. Kim's impactful research has been recognized through several awards, including the Young Investigator Award and the Merit Award from the Conque Cancer Foundation with the American Society of Clinical Oncology, as well as the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
Clinical Specialties
Fact Sheets
Bladder Cancer
Learn More on Yale MedicineProstate Cancer
Learn More on Yale MedicineTesticular Cancer
Learn More on Yale MedicineTelomere Research
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
- August 11, 2023
Study Shows Promise of Immunotherapy Treatment for Penile Cancer
- June 11, 2023
Profiles in Survivorship: John Bova
- January 10, 2023
Yale Cancer Center Presents 2022 Research Awards
Related Links
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.